About Us.
2025
01.
Anti-Alzheimer drug BEY2153: approved phase II IND in Alzheimer’s disease trial
03.
Fifth fund raising
2024
01.
Substance patent registered in New Zealand
03.
Anti-Alzheimer drug BEY2153: confirmed the competitiveness as disease modifying drug of Alzheimer’s disease, first time in the world
06.
Anti-cancer drug BEY1107: completed IP formulation study and production as tablet
07.
Anti-cancer drug BEY4101: confirmed the competitiveness in blood cancer treatment
08.
Process patent registered in China
09.
Anti-cancer drug BEY1107: approved phase Ib/II IND amendment in colorectal cancer trial
11.
Anti-cancer drug BEY4101: completed IP formulation study and production as tablet
2023
01.
Anti-Alzheimer drug BEY2153: started full swing preparation of phase 2 in Alzheimer’s disease
02.
Polymorph patent registered in South Korea
04.
Substance patent registered in Canada
10.
Process patent registered in Japan
11.
Substance patent registered in Brazil
12.
Anti-cancer drug BEY4101: confirmed the competitiveness in NSCLC in vivo model study
2022
04.
Anti-cancer drug BEY1107: : approved phase Ib/II IND amendment in pancreatic cancer trial
05.
Completed office building construction in ISBB (Dungok district)
09.
Anti-cancer drug BEY1107: approved phase Ib/II IND amendment in colorectal cancer trial
Process patent registered in South Korea
10.
Anti-Alzheimer drug BEY2153: completed phase 1 clinical trial and submitted CSR to KFDA
11.
Awarded ‘Excellent (S)’ grade by Ministry of Science and ICT (MSIT) in 5-year final evaluation
2021
01.
Anti-cancer drug BEY1107: completed phase Ib combination therapy dose escalation in pancreatic cancer trial
Substance patent registered in Singapore
04.
Anti-cancer drug BEY1107: approved phase Ib/II IND in colorectal cancer trial
09.
Fourth fund raising
10.
Anti-cancer drug BEY1107: approved phase Ib IND in GBM trial
Substance patent registered in India
2020
01.
Anti-cancer drug BEY1107: completed phase I monotherapy dose escalation in pancreatic cancer trial
Substance patent registered in Russia
03.
Substance patent registered in Australia
04.
Substance patent continuation application (CA) registered in the U.S.
07.
Anti-Alzheimer drug BEY2153: entered phase I trial
12.
Substance patent registered in Europe and Israel
2019
01.
Selected securities company for IPO
03.
Substance patent registered in the U.S.
11.
Substance patent registered in China and Japan
2018
01.
Anti-cancer drug BEY1107: applied for IND for phase I/II clinical trial
Approved as venture company (Venture capital association)
02.
Anti-cancer drug BEY1107: IND approved for phase I/II clinical trial
04.
Granted by the Ministry of Health and Welfare (MOHW) (2 years)
Series C investment raised (allotment to third party)
05.
Anti-cancer drug BEY1107: begins phase I/II clinical trial
2017
01.
Anti-Alzheimer drug BEY2153: entered into non-clinical study (GLP)
BEY4101: entered into non-clinical study (GLP)
03.
Awarded ‘Excellent (S)’ grade by Ministry of Science and ICT (MSIT) in 2-year final evaluation
04.
Granted by the Ministry of Science and ICT (MSIT) (5 years)
08.
Applied for patent in major foreign countries
09.
Domestic product patent registered
12.
Industrial land allotted at International Science Business Belt (Dungok district)
2016
06.
Anti-cancer drug BEY1107: completed non-clinical study (GLP)
Series B investment raised (allotment to third party)
2015
01.
Anti-cancer drug BEY1107: entered into non-clinical study (GLP)
06.
Granted by the Ministry of Science and ICT (MSIT) (5 years)
12.
Approved as venture company (Venture capital association)
2014
03.
Approved as company-affiliated R&D center
05.
Granted by the Small Medium Business Administration (SMBA)
06.
Series A investment raised (allotment to third party)
08.
Granted by Daejeon Technopark
11.
Granted by the Small Medium Business Administration (SMBA)
12.
Granted by the Ministry of Science and ICT (MSIT) (2 years)
2013
06.
Founded BeyondBio Inc.
11.
Approved as Research & Development Dedicated Department
12.
Approved as venture company (Korea Technology Finance Corporation)
42, Gukjegwahak 13-ro, Yuseong-gu, Daejeon, 34002, Rep of Korea
Copyright (c) 2010 BEYONDBIO Inc. All rights reserved.
